Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.61 |
| ▸ | PAK4 | O96013 | 1/20 | 0.61 |
| ▸ | CSF1R | P07333 | 1/20 | 0.61 |
| ▸ | GRK5 | P34947 | 1/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.61 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.61 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.61 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.61 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.61 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.61 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1933137 | 0.87 | PIK3CG (0.52) | RETMAP4K4PAK4CSF1RGRK5 | |
| SCHEMBL12909565 | 0.84 | PIK3CG (0.50) | RETMAP4K4PAK4CSF1RGRK5 | |
| SCHEMBL939045 | 0.84 | PIK3CG (0.54) | RETMAP4K4PAK4CSF1RGRK5 | |
| Hydrochloric Acid SCHEMBL933897 | 0.83 | PIK3CG (0.49) | RETMAP4K4PAK4CSF1RGRK5 | |
| SCHEMBL1932766 | 0.82 | PIK3CG (0.49) | RETMAP4K4PAK4CSF1RGRK5 | |
| SCHEMBL12909577 | 0.81 | PIK3CG (0.48) | RETMAP4K4PAK4CSF1RGRK5 | |
| SCHEMBL938836 | 0.81 | PIK3CG (0.48) | RETMAP4K4PAK4CSF1RGRK5 | |
| SCHEMBL938224 | 0.81 | RAB9A (0.50) | RETMAP4K4PAK4CSF1RGRK5 | |
| SCHEMBL936441 | 0.81 | PIK3CG (0.51) | RETMAP4K4PAK4CSF1RGRK5 | |
| SCHEMBL936706 | 0.80 | PIK3CG (0.58) | DYRK1APIK3CGPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222674-B1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LTD (GB) | 2015-11-11 | — | — | EP | claimed |
| US-8865699-B2 | Amino triazoles as PI3K inhibitors | CELLZOME LTD. (GB) | 2014-10-21 | — | — | US | claimed |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2011-01-27 | — | — | US | claimed |
| EP-2222674-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | Cellzome Limited (GB) | 2010-09-01 | — | — | EP | claimed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | claimed |
| EP-3204007-B1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1 INC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-9926315-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926315-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926315-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170233388-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2017-08-17 | — | — | US | disclosed |
| US-8865699-B2 | Amino triazoles as PI3K inhibitors | CELLZOME LTD. (GB) | 2014-10-21 | — | — | US | disclosed |
| US-20120041195-A1 | Heterocyclic compounds | FOVEA PHARMACEUTICALS | 2012-02-16 | — | — | US | disclosed |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| EP-2222674-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | Cellzome Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | CFTR, KCNJ11, KCNJ1 | RET 2507/4885MAP4K4 1125/4885PAK4 2045/4885 |
| US-20120041195-A1 | Heterocyclic compounds | MAP3K1, MAP3K5, MAP3K2 | RET 289/4885MAP4K4 24/4885PAK4 219/4885 |
| US-20170233388-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, KCNJ11, KCNJ1 | RET 2507/4885MAP4K4 1125/4885PAK4 2045/4885 |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | PIK3C3, PIK3R3, PIK3R5 | RET 908/4885MAP4K4 454/4885PAK4 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.